Abstract
Public health surveillance for pathogens presents an optimization problem: we require enough sampling to identify intervention-triggering shifts in pathogen epidemiology, such as new introductions or sudden increases in prevalence, but not so much that costs due to surveillance itself outweigh those from pathogen-associated illness. To determine this optimal sampling frequency, we developed a general mathematical model for the introduction of a new pathogen that, once introduced, increases in prevalence exponentially. Given the relative cost of infection vs. sampling, we derived equations for the expected combined cost of disease burden and surveillance given a sampling frequency and thus the sampling frequency for which the expected total cost is lowest.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has been funded in part by contract 200-2016-91779 with the Centers for Disease Control and Prevention. Disclaimer: The findings, conclusions, and views expressed are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). S.M.K. received funding from NIH T32 training grant 2 T32 AI 7535-21 A1. M.L. is grateful for funding from the Morris-Singer Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All code for running the simulations and reproducing the figures is available at https://github.com/jolejarz.
